CTLA4 and neoplasm: Under normal circumstances, the PD-l/PD-L1 and CTLA-4/B7 checkpoint pathways prevent aberrantly activated T cells from causing autoimmunity; therefore, expression of these ligands by tumor cells allows circumvention of the immune system.